logo
  

AstraZeneca's Lynparza Granted Priority Review In U.S. For High-risk Early Breast Cancer

AstraZeneca Plc. (AZN.L,AZN) said that its supplemental New Drug Application or sNDA for Lynparza or olaparib has been granted Priority Review in the US for the adjuvant treatment of patients with BRCA-mutated or BRCAm HER2-negative high-risk early breast cancer who have already been treated with chemotherapy either before or after surgery.

The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, is during the first quarter of 2022.

Lynparza is being jointly developed and commercialized by AstraZeneca and Merck & Co., Inc.

The sNDA was based on results from the OlympiA Phase III trial. The results showed Lynparza demonstrated a statistically significant and clinically meaningful improvement in invasive disease-free survival (iDFS), reducing the risk of invasive breast cancer recurrence, second cancers or death by 42% versus placebo.

Lynparza is approved in the US, EU, Japan and several other countries for the treatment of patients with germline BRCAm, HER2-negative, metastatic breast cancer previously treated with chemotherapy based on results from the OlympiAD Phase III trial. In the EU, this indication also includes patients with locally advanced breast cancer.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the second quarter on Wednesday, off-price retailer TJX Companies, Inc. (TJX) provided financial outlook for the third and the fourth quarters as well as slashed its guidance for the full-year 2023. For the third quarter, the company projects earnings in a range... American Airlines announced an agreement to purchase up to 20 Overture supersonic jets, the world's fastest airliner, from transportation start-up Boom Supersonic, with an option for an additional 40. Overture, which is expected to carry passengers at twice the speed of the fastest commercial aircraft available at present, would provide an important new speed advantage to American's fleet. WhatsApp, an instant messaging app owned by Meta Platforms, has launched a new desktop app for Windows users. The company is also developing an app native to Mac operating systems. Till now, WhatsApp Desktop users have been using its web-based desktop app i.e., WhatsApp Desktop, or browser-based app, i.e., WhatsApp Web. They were using the old Electron technology.
Follow RTT